Branded? Generic? They're Both Doing Great!

Which is more impressive: a 21% increase in U.S. sales of a high-margin drug or a 14% increase in U.S. sales of low-margin products? Normally the choice would be clear, but in Teva Pharmaceutical's (Nasdaq: TEVA  ) case, I'm going to have to go with the slower-but-still-impressive generic drug sales growth.

That's not to say the 21% increase in sales of its multiple sclerosis drug Copaxone isn't impressive; there's tough competition out there from Biogen Idec's (Nasdaq: BIIB  ) Avonex, Tysabri from Biogen and Elan (NYSE: ELN  ) , Rebif from Pfizer (NYSE: PFE  ) and EMD Serono, and others.

But Copaxone will face generic competition at some point -- sooner rather than later if Momenta Pharmaceuticals (Nasdaq: MNTA  ) and Mylan (Nasdaq: MYL  ) have their way -- and Copaxone will soon see competition from an oral treatment for multiple sclerosis if the Food and Drug Administration approves Novartis' (NYSE: NVS  ) Gilenia.

Generic drugs, on the other hand, seem to provide a never-ending supply of growth. Branded drugs are constantly losing patent protection -- Teva launched nine new products in the U.S. this quarter -- and the global push to decrease health-care costs should increase the use of generics. Plus, Teva has some ability to push margins higher as it increases in size. The company expects to close on its acquisition of Ratiopharm this quarter, and I doubt it's done growing yet.

The strong quarter on both fronts pushed Teva to increase the lower end of its 2010 guidance; the company now expects adjusted earnings to come in between $4.50 and $4.60 per share. That values the company at about 11 times this year's earnings. It is not exactly a cheap generic, but it isn't all that expensive if Teva can keep up the stellar growth.

Looking for more opinions of Teva? Rick Steier and I squared off in April. Go read them and then give us your opinion in Motley Fool CAPS.

Pfizer is a Motley Fool Inside Value recommendation. Elan and Momenta Pharmaceuticals are Rule Breakers choices. Novartis is a Global Gains recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1247839, ~/Articles/ArticleHandler.aspx, 10/25/2014 3:13:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement